# Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

> **NCT06997276** · PHASE1 · RECRUITING · sponsor: **SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany** · enrollment: 32 (estimated)

## Conditions studied

- Healthy
- Hepatic Impairment

## Interventions

- **DRUG:** Mirdametinib (MEK Inhibitor)

## Key facts

- **NCT ID:** NCT06997276
- **Lead sponsor:** SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997276, "Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06997276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*